Skip to main content
. 2020 Nov 10;10:19416. doi: 10.1038/s41598-020-76375-w

Figure 5.

Figure 5

Effects of Y120F and Q125H mutations in patient-derived Nef clones on counteraction of SERINC3/5-mediated infectivity inhibition and modulation of cell surface receptor expression. Patient-derived Nef clones (n = 10) harboring HLA-B*51:01-adapted 120F and 125H mutations (see legend to Fig. 4B) were subcloned into HIV-1 pNL43 or Nef-GFP fusion plasmids, and their corresponding Y120 and Q125 reversion mutants were constructed. Pair-wise analyses of Nef’s ability to counteract SERINC3/5 (A) as well as downregulate CD4, CCR5, CXCR4 and HLA class I, and upregulate CD74 (B) were conducted. Data represent indicated Nef functions by parental and revertant clones. Data shown are the mean results ± SD from 3 or 4 independent experiments. Statistical analysis was performed by the Wilcoxon matched-pairs signed rank test. n.s. not significant.